Jordi Ponce

Dr. Jordi Ponce

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ICIrene Campoy
Irene Campoy
LLLucia Lanau
Lucia Lanau
TATatiana Altadill
Tatiana Altadill
TSTamara Sequeiros
Tamara Sequeiros
SCSílvia Cabrera
Sílvia Cabrera
ECEva Colas
Eva Colas
Uterine aspirates are used in the diagnostic process of endometrial disorders, yet further applications could emerge if its complex milieu was simplified. Exosome-like vesicles isolated from uterine aspirates could become an attractive source of biomarkers, but there is a need to standardize isolation protocols. The objective of the study was to determine whether exosome-like vesicles exist in the fluid fraction of uterine aspirates and to compare protocols for their isolation, characterization, and analysis. We collected uterine aspirates from 39 pre-menopausal women suffering from benign gynecological diseases. The fluid fraction of 27 of those aspirates were pooled and split into equal volumes to evaluate three differential centrifugation-based procedures: (1) a standard protocol, (2) a filtration protocol, and (3) a sucrose cushion protocol. Characterization of isolated vesicles was assessed by electron microscopy, nanoparticle tracking analysis and immunoblot. Specifically for RNA material, we evaluate the effect of sonication and RNase A treatment at different steps of the protocol. We finally confirmed the efficiency of the selected methods in non-pooled samples. All protocols were useful to isolate exosome-like vesicles. However, the Standard procedure was the best performing protocol to isolate exosome-like vesicles from uterine aspirates: nanoparticle tracking analysis revealed a higher concentration of vesicles with a mode of 135 ± 5 nm, and immunoblot showed a higher expression of exosome-related markers (CD9, CD63, and CD81) thus verifying an enrichment in this type of vesicles. RNA contained in exosome-like vesicles was successfully extracted with no sonication treatment and exogenous nucleic acids digestion with RNaseA, allowing the analysis of the specific inner cargo by Real-Time qPCR. We confirmed the existence of exosome-like vesicles in the fluid fraction of uterine aspirates. They were successfully isolated by differential centrifugation giving sufficient proteomic and transcriptomic material for further analyses. The Standard protocol was the best performing procedure since the other two tested protocols did not ameliorate neither yield nor purity of exosome-like vesicles. This study contributes to establishing the basis for future comparative studies to foster the field of biomarker research in gynecology.

24 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CHChiara Herzog
Chiara Herzog
FMFátima Marín
Fátima Marín
AJAllison Jones
Allison Jones
IEIona Evans
Iona Evans
DRDaniel Reisel
Daniel Reisel
MWMartin Widschwendter
Martin Widschwendter
PURPOSE: Endometrial cancer (EC) incidence has been rising over the past 10 years. Delays in diagnosis reduce survival and necessitate more aggressive treatment. We aimed to develop and validate a simple, noninvasive, and reliable triage test for EC to reduce the number of invasive diagnostic procedures and improve patient survival. METHODS: We developed a test to screen and triage women with suspected EC using 726 cervical smear samples from women with and without EC, and validated the test in 562 cervicovaginal samples using three different collection methods (cervical smear: n = 248; vaginal swab: n = 63; and self-collection: n = 251) and four different settings (case/control: n = 388; cohort of women presenting with postmenopausal bleeding: n = 63; a cohort of high-risk women with Lynch syndrome: n = 25; and a nested case/control setting from a screening cohort and samples taken up to 3 years before EC diagnosis: n = 86). RESULTS: We describe the Women's cancer risk IDentification – quantitative polymerase chain reaction test for Endometrial Cancer (WID-qEC), a three-marker test that evaluates DNA methylation in gene regions of GYPC and ZSCAN12. In cervical, self-collected, and vaginal swab samples derived from symptomatic patients, it detected EC with sensitivities of 97.2% (95% CI, 90.2 to 99.7), 90.1% (83.6 to 94.6), and 100% (63.1 to 100), respectively, and specificities of 75.8% (63.6 to 85.5), 86.7% (79.3 to 92.2), and 89.1% (77.8 to 95.9), respectively. The WID-qEC identified 90.9% (95% CI, 70.8 to 98.9) of EC cases in samples predating diagnosis up to 1 year. Test performance was similar across menopausal status, age, stage, grade, ethnicity, and histology. CONCLUSION: The WID-qEC is a noninvasive reliable test for triage of women with symptoms suggestive of ECs. Because of the potential for self-collection, it could improve early diagnosis and reduce the reliance for in-person visits.

1 July 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
AGAmparo García-Tejedor
Amparo García-Tejedor
JMJose M. Martinez-Garcia
Jose M. Martinez-Garcia
BEBEATRIZ CANDÁS ESTÉBANEZ
BEATRIZ CANDÁS ESTÉBANEZ
ESElena Suarez
Elena Suarez
LMLaura Mañalich
Laura Mañalich
JPJordi Ponce
Jordi Ponce

1 February 2020 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
IVIgnace Vergote
Ignace Vergote
JMJavier F. MAGRINA
Javier F. MAGRINA
VZVanna Zanagnolo
Vanna Zanagnolo
PMPaul M. Magtibay
Paul M. Magtibay
KBKristina Butler
Kristina Butler
Philippe Van TrappenPhilippe Van Trappen
Philippe Van Trappen

13 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DCDavid Cibula
David Cibula
MBMartina Borčinová
Martina Borčinová
SMSimone Marnitz-Schulze
Simone Marnitz-Schulze
JJJiří Jarkovský
Jiří Jarkovský
JKJaroslav Klát
Jaroslav Klát
RKRoman Kocian
Roman Kocian
Background: To prospectively assess LLL incidence among cervical cancer patients treated by uterine surgery complemented by SLN biopsy, without PLND. Methods: A prospective study in 150 patients with stage IA1–IB2 cervical cancer treated by uterine surgery with bilateral SLN biopsy. Objective LLL assessments, based on limb volume increase (LVI) between pre- and postoperative measurements, and subjective patient-perceived swelling were conducted in six-month periods over 24-months post-surgery. Results: The cumulative incidence of LLL at 24 months was 17.3% for mild LLL (LVI 10–19%), 9.2% for moderate LLL (LVI 20–39%), while only one patient (0.7%) developed severe LLL (LVI > 40%). The median interval to LLL onset was nine months. Transient edema resolving without intervention within six months was reported in an additional 22% of patients. Subjective LLL was reported by 10.7% of patients, though only a weak and partial correlation between subjective-report and objective-LVI was found. No risk factor directly related to LLL development was identified. Conclusions: The replacement of standard PLND by bilateral SLN biopsy in the surgical treatment of cervical cancer does not eliminate the risk of mild to moderate LLL, which develops irrespective of the number of SLN removed.

Verified
Journal Article
Open access
PDF file
ESElisenda Alsina Sanchis
Elisenda Alsina Sanchis
AFAgnès Figueras
Agnès Figueras
ALAlvaro Lahiguera
Alvaro Lahiguera
MMMarta Gil Martin
Marta Gil Martin
BPBeatriz Pardo
Beatriz Pardo
FVFrancesc Viñals
Francesc Viñals
There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development.